zelicapavir
Small molecule
Evidence outlook · lead readout
RSVHR (NCT05568706) · Respiratory Syncytial Virus Infection
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
RSVHR (NCT05568706): RSVHR was a randomized, double-blind, placebo-controlled Phase 2b trial in 186 non-hospitalized adults with RSV at high risk of complications, given zelicapavir 800 mg (n=121) or placebo (n=65) once daily for 5 days. The sponsor states that no effect was seen on the primary endpoint, time to resolution of the four lower respiratory tract symptoms to mild, so the primary was missed. The sponsor reports faster resolution on secondary and subgroup measures (HR3 population), but those are not the primary. Source: the sponsor's topline release filed with the SEC (8-K exhibit 99.1, 29 Sep 2025) and CT.gov posted results.
Result from the sponsor's press release and CT.gov posted medians; no peer-reviewed publication was found.
Company guidance: topline data expected 1Q 2027 (Enanta Pharmaceuticals, Inc., 16 Nov 2026). “Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q 2027” Source ↗
Company guidance: data expected in 2027 (NCT07908381; Enanta Pharmaceuticals, Inc., 16 Nov 2026). “We also began dosing patients in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe disease and anticipate reporting data from the Phase 2b portion in 2027,” said Jay R.” Source ↗
Company guidance: topline data expected in 2027 (NCT07908381; Enanta Pharmaceuticals, Inc., 18 Nov 2026). “Topline data from the Phase 2b portion of RESOLVE are expected in 2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03750383 NCT03750383 · Respiratory Syncytial Virus Infection Registry: NCT03750383 | 1 | Cmax of EDP-938 with and without coadministration with cyclosporine (Up to 12 days); AUC of EDP-938 with and without coadministration with cyclosporine (Up to 12 days); Cmax of EDP-938 with and without coadministration with prednisone (Up to 21 days); AUC of EDP-938 with and without coadministration with prednisone (Up to 21 days) 2018-11-17 | Cyclosporine raised EDP-938 AUC0-inf about 1.4-fold (weak effect). | not yet graded | link ↗ |
View 2 more trials
RSVTx NCT04633187 · Respiratory Syncytial Virus Infection This trial enrolled only 9 patients (5 on drug, 4 on placebo) and ended without reaching a larger planned size, so it was severely underpowered for its primary comparison. No statistical test was reported for the primary endpoint, and the small numeric difference (0 of 5 vs 1 of 4 patients with a complication) cannot reliably show whether the drug worked. Registry: NCT04633187 | 2 | Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication (Day 1 through Day 28) 2023-05-31 | Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication (Day 1 through Day 28): EDP-938 0 Participants | Placebo 1 Participants | Weak signal | link ↗ |
RSVHR NCT05568706 · Respiratory Syncytial Virus Infection RSVHR was a randomized, double-blind, placebo-controlled Phase 2b trial in 186 non-hospitalized adults with RSV at high risk of complications, given zelicapavir 800 mg (n=121) or placebo (n=65) once daily for 5 days. The sponsor states that no effect was seen on the primary endpoint, time to resolution of the four lower respiratory tract symptoms to mild, so the primary was missed. The sponsor reports faster resolution on secondary and subgroup measures (HR3 population), but those are not the primary. Source: the sponsor's topline release filed with the SEC (8-K exhibit 99.1, 29 Sep 2025) and CT.gov posted results. Result from the sponsor's press release and CT.gov posted medians; no peer-reviewed publication was found. Registry: NCT05568706 | 2 | Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms (Day 1 through Day 33); Time to Complete Resolution of LRTD Symptoms for the mITT Population (Day 1 through Day 33); Time to Complete Resolution of LRTD Symptoms for the HR3 Population (Day 1 through Day 33) 2025-06-23 | Time to resolution of the four LRTD symptoms to mild (primary), zelicapavir 800 mg daily for 5 days vs placebo: median 5.0 vs 4.1 days (CT.gov), with no effect per the sponsor. Time to complete LRTD symptom resolution: 12.5 vs 13.0 days (mITT) and 12.0 vs 15.0 days (HR3), no test posted. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Respiratory Syncytial Virus Infection: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zelicapavir: this drug | Phase 2 | Small molecule | RSV N protein (nucleoprotein) | Weak signal | NCT05568706: Time to resolution of the four LRTD symptoms to mild (primary), zelicapavir 800 mg daily for 5 days vs placebo: median 5.0 vs 4.1 days (CT.gov), with no effect per the sponsor. Time to complete LRTD symptom resolution: 12.5 vs 13.0 days (mITT) and 12.0 vs 15.0 days (HR3), no test posted. missed NCT04633187: Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication (Day 1 through Day 28): EDP-938 0 Participants | Placebo 1 Participants | |
| Clesrovimab (Enflonsia) | Approved | Monoclonal antibody | RSV F protein | not yet graded | No reviewed efficacy summary in this indication | |
| mRESVIA | Approved | Vaccine | RSV pre-F protein | Partial signal | NCT05330975: Part A (mRNA-1345 with Afluria Quadrivalent vs mRNA-1345 alone), RSV-A day 29: GMT ratio 0.807 (95% CI 0.668 to 0.974), lower bound above 0.667, non-inferior; seroresponse difference -11.2% (95% CI -17.9 to -4.1), lower bound below -10%, non-inferiority not shown. Part B (with SARS-CoV-2 vaccine): RSV-A GMT ratio 0.796 (95% CI 0.702 to 0.901) and seroresponse difference -4.4% (95% CI -9.9 to 1.0), both non-inferior (CT.gov posted analyses). | |
| EDP-323 | Phase 2 | Small molecule | RSV L protein | Partial signal | NCT06170242: Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) (Day 1 to Day 12): EDP-323 High Dose 99.05 log10 copies/mL*hours (Standard Deviation 133.325) | EDP-323 Low Dose 82.28 log10 copies/mL*hours (Standard Deviation 158.033) | Placebo 657.45 log10 copies/mL*hours (Standard Deviation 396.743) | |
| GSK5893818 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0256 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0291 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0340 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0341 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow zelicapavir to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2029 (1)
July 2029 (1)
Company guidance: data expected in 2027 (Enanta Pharmaceuticals, Inc., 16 Nov 2026). “We also began dosing patients in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe disease and anticipate reporting data from the Phase 2b portion in 2027,” said Jay R.” Source ↗
Company guidance: topline data expected in 2027 (Enanta Pharmaceuticals, Inc., 18 Nov 2026). “Topline data from the Phase 2b portion of RESOLVE are expected in 2027.” Source ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent